Posts from the ‘FDA December 2013 Orphan Designations’ Category

• SUBSCRIBE VIA EMAIL

  Click to follow & receive notifications of new posts by email.

  Email Address:

  Subscriber Via Email

• SUBSCRIBE VIA RSS FEED

  Subscribe in a reader

• BLOG STATS

  • 378,795 hits

• 2nd Rare Disease Collaboration Summit

  

  The Orphan Druganaut Blog is a Media Partner.

• SEARCH

• Categories

  Categories Select Category 3D Printing  (1) AAV1-FS344  (2) AbbVie  (4) Abeona Therapeutics  (5) ACADIA Pharmaceuticals  (2) Acceleron Pharma  (1) Achromatopsia  (1) Actelion Pharmaceuticals  (1) Actimmune  (2) Acute Heart Failure  (1) Acute Lymphoblastic Leukemia  (8) Acute Myeloid Leukemia  (2) Adalimumab  (1) ADCETRIS  (3) Adenosine Deaminase Severe Combined Immunodeficiency Syndrome  (1) Adrenoleukodystrophy (ALD)  (2) Aduro BioTech  (1) Aegerion Pharmaceuticals  (22) Aeterna Zentaris  (1) Afatinib  (1) Afibercept  (1) Aflibercept  (1) Agilis Biotherapeutics  (2) Agios Pharmaceuticals  (1) aHUS  (1) Akashi Therapeutics  (1) Aldeyra Therapeutics  (2) Aldoxorubicin  (1) Alectinib  (1) Alexion Pharmaceuticals  (21) Alirocumab  (1) Alkaptonuria  (2) ALN-TTR02  (2) Alnylam Pharmaceuticals  (2) Alprolix  (2) ALS  (2) Amgen  (2) Ampligen  (11) Amyloidosis  (3) Amyotrophic Lateral Sclerosis  (3) Anascorp  (1) Angelman Syndrome  (1) Applied Genetic Technologies Corporation (AGTC)  (2) Apremilast  (2) Ariad Pharmaceuticals  (6) Arikace  (1) Arikayce  (1) ArmaGen  (1) Arzerra  (2) Asfotase Alfa  (1) AstraZeneca  (1) Asunaprevir  (1) Ataluren  (5) Atara Biotherapeutics  (1) Atopic Dermatitis  (1) Atryn  (1) Atterocor  (1) ATTR  (2) Audentes Therapeutics  (4) Auspex Pharmaceuticals  (1) Australia  (10) AveXis  (2) AZD9291  (1) Barth Syndrome  (2) Baxalta  (1) Baxter International  (1) Bayer  (4) Becker Muscular Dystrophy  (3) Behcet’s Disease  (3) Belinostat  (1) Berinert  (1) Bexsero  (2) Bimagrumab  (1) BioBlast Pharma  (2) Biogen Idec  (5) BioMarin Pharmaceutical  (5) Biomarkers  (2) Bivalent rLP2086 Vaccine  (1) Bladder Cancer  (1) Blexion Pharmaceuticals  (1) Blinatumomab  (2) Blincyto  (1) Blog  (1) Blogs  (1) Bluebird bio  (2) Boehringer Ingelheim  (4) Books  (4) Boston Children’s Hospital  (1) Bosulif  (2) Bosutinib  (3) Brain Metastasis  (1) Brazil  (1) Breast Cancer  (2) Brentuximab vedotin  (2) Bristol-Meyers Squibb  (1) Bristol-Myers Squibb  (4) Bronchitol  (5) Buphenyl  (1) Cabozantinib  (12) Campath  (5) Canada  (16) Canavan Disease  (1) Cancer  (37) Capricor Therapeutics  (1) Carfilzomib  (1) Catalyst Pharmaceutical Partners  (2) Celgene  (10) Cell Therapeutics  (1) Celladon Corporation  (1) Celldex Therapeutics  (1) Celsion  (3) Central Precocious Puberty (CPP)  (1) Cerdelga  (3) Cerezyme  (12) Ceritinib  (1) Charcot-Marie-Tooth Disease  (1) Chiesi Farmaceutici S.p.A.  (1) Children’s Hospital of Los Angeles  (1) Children’s Hospital of Philadelphia (CHOP)  (1) Children’s Hospital of Pittsburgh  (1) China  (7) Choroideremia  (1) Chronic Fatigue Syndrome  (8) Chronic Lymphocytic Leukemia  (9) Chronic Myelogenous Leukemia (CML)  (6) Cincinnati Children’s Hospital Medical Center  (1) Cinryze  (3) Cleveland BioLabs  (1) Cleveland’s Nationwide Children’s Hospital  (1) Clinical Trials  (3) Clovis Oncology  (2) Columbia University Medical Center  (1) Cometriq  (10) Coté Orphan  (1) Crizotinib  (2) Crohn’s Disease  (1) Crowdfunding  (4) CSL Behring  (4) Cushing’s Disease  (3) Cyclic Pyranopterin Monophosphate  (1) Cydan  (2) Cyramza  (1) Cysteamine Bitartrate  (5) Cystic Fibrosis  (86) CytRx Corporation  (1) Dabrafenib  (5) Daclatasvir  (1) Daratumumab  (1) Darinaparsin  (1) Dart Therapeutics  (2) DBV Technologies  (1) Debiopharm  (1) Deflazacort  (1) Depomed  (3) Dexpramipexole  (1) Diabetic Retinopathy  (4) Diffusion Pharmaceuticals  (1) Dimension Therapeutics  (1) Dinutuximab  (1) DNA  (2) Drisapersen  (12) Duchenne Muscular Dystrophy  (71) Dupilumab  (1) Dyax  (4) Ebola Virus  (3) Eculizumab  (16) Edimer Pharmaceuticals  (1) Edison Pharmaceuticals  (2) Eisai Co.  (1) Elelyso  (21) Eli Lilly  (2) Eliglustat  (3) Eliglustat Tartrate  (6) Eloctate  (1) Elosulfase Alfa  (1) Elotuzumab  (1) Eltrombopag  (2) Embonate  (1) End-Of-Life Care  (1) Entinostat  (1) Entrectinib  (1) Enzyme Replacement Therapy  (1) EPI-743  (1) Epidermolysis Bullosa  (7) Epizyme  (1) Esbriet  (1) EspeRare Foundation  (1) Eteplirsen  (48) European Medicines Agency (EMA)  (54) EURORDIS  (4) Exelixis  (10) Expensive Orphan Drugs  (7) Eylea  (3) Fate Therapeutics  (1) FDA Advisory Committee Meetings  (16) FDA April 2013 Orphan Designations  (1) FDA April 2014 Orphan Designations  (1) FDA April 2015 Orphan Designations  (1) FDA August 2012 Orphan Designations  (1) FDA August 2013 Orphan Designations  (1) FDA August 2014 Orphan Designations  (1) FDA Breakthrough Therapy Designation  (149) FDA December 2012 Orphan Designations  (1) FDA December 2013 Orphan Designations  (1) FDA December 2014 Orphan Designations  (1) FDA February 2013 Orphan Designations  (1) FDA February 2014 Orphan Designations  (2) FDA February 2015 Orphan Designations  (1) FDA January 2013 Orphan Designations  (1) FDA January 2014 Orphan Designations  (1) FDA January 2015 Orphan Designations  (1) FDA July 2012 Orphan Designations  (1) FDA July 2013 Orphan Designations  (1) FDA July 2014 Orphan Designations  (1) FDA June 2013 Orphan Designations  (1) FDA June 2014 Orphan Designations  (1) FDA March 2013 Orphan Designations  (1) FDA March 2014 Orphan Designations  (1) FDA March 2015 Orphan Designations  (1) FDA May 2013 Orphan Designations  (1) FDA May 2014 Orphan Designations  (1) FDA May 2015 Orphan Designations  (1) FDA November 2012 Orphan Designations  (1) FDA November 2013 Orphan Designations  (1) FDA November 2014 Orphan Designations  (1) FDA October 2012 Orphan Designations  (1) FDA October 2013 Orphan Designations  (1) FDA October 2014 Orphan Designations  (1) FDA Safety & Innovation Act (S. 3187)  (15) FDA September 2012 Orphan Designations  (1) FDA September 2013 Orphan Designations  (2) FDA September 2014 Orphan Designations  (1) Fenretinide  (1) Fibrocell Science  (1) Fibrocell Technologies  (1) Findacure  (7) Firazyr  (1) Firdapse  (2) Follistatin  (3) Fragile X-Associated Disorders  (1) Friedreich’s ataxia  (4) Friedriech’s Ataxia  (3) Fun Facts  (5) Gabapentin  (1) Gallus Biopharmaceuticals  (1) Gastric Cancer  (1) Gastro-Esophageal Junction Adenocarcinoma  (1) Gastrointestinal Stromal Tumors (GIST)  (2) Gattex  (32) Gaucher Disease  (26) Gazyva  (2) Gene Therapy  (36) Genentech  (7) Genmab  (2) Genomic Sequencing  (2) Genzyme  (45) Germany  (1) Gevokizumab  (1) Giant Axonal Neuropathy  (3) Gilead Sciences  (5) Gilotrif  (1) GlaxoSmithKline  (22) Gleevec  (2) Glioblastoma  (2) Glioblastoma Multiforme  (2) Glioma  (1) Global Genes  (1) Glybera  (4) Gralise  (3) Halo Therapeutics  (1) Halozyme Therapeutics  (1) Harvoni  (1) HCV  (2) Heart Failure  (1) Hemispherx BioPharma  (8) Hemophagocytic Lymphohistiocytosis  (1) Hemophilia  (7) Hemophilia A  (5) Hemophilia B  (7) Hepatitis C  (9) Hepatocellular Carcinoma  (1) Hereditary Angioedema(HAE)  (9) Hereditary Inclusion Body Myopathy (HIBM)  (2) Hidradenitis Suppurativa  (1) HIV/AIDS  (2) Hodgkin lymphoma (HL)  (2) Holoclar  (1) Hologic  (7) Homozygous Familial Hypercholesterolemia  (23) Horizon Pharma  (2) HudsonAlpha Institute For Biotechnology  (1) Humira  (1) Hunter Syndrome  (1) Huntington’s Disease  (2) Hurler’s Syndrome  (2) Hypoparathyroidism  (2) Hypophosphatasia  (1) Ibalizumab  (1) Ibrance  (1) Ibrutinib  (4) Iclusig  (3) Idarucizumab  (1) Idelalisib  (2) Idiopathic Pulmonary Fibrosis  (2) Ignyta Inc.  (1) Imatinib  (2) Imbruvica  (3) Immune Response BioPharma  (1) Impavido  (1) Incuron  (1) Incyte Corporation  (4) Initial Public Offering  (13) Insmed  (2) Intercept Pharmaceuticals  (1) Interferon Gamma-1b  (1) InterMune  (1) Intrexon Corporation  (2) Ipsen Biopharmaceuticals  (1) Ireland  (1) Isis Pharmaceuticals  (14) Ivacaftor  (77) Ixazomib  (1) Jakafi  (1) Jakavi  (4) Janssen Biotech  (1) Janssen Research & Development  (1) Japan  (7) Juno Therapeutics  (4) Juxtapid  (13) K-V Pharmaceutical  (28) Kalbitor  (1) Kalydeco  (81) Keytruda  (3) Kynamro  (16) Kyprolis  (1) LAM Therapeutics  (2) Lambert-Eaton Myasthenic Syndrome  (2) Lambrolizumab  (1) Laurent Pharmaceuticals  (1) LDK378  (2) Lebrikizumab  (1) Leigh Syndrome  (1) Leishmaniasis  (1) Lemtrada  (4) Lenalidomide  (3) Lenvatinib  (1) Limbal Stem Cell Deficiency  (1) Lipoprotein Lipase Deficiency  (2) List Of Orphan Drugs  (1) Lojuxta  (2) Lomitapide  (24) Lucentis  (2) Lumacaftor  (1) Lumena Pharmaceuticals  (1) Lurbinectedin  (6) Lymphangioleiomyomatosis  (3) Lysogene  (1) Lysosomal Acid Lipase (LAL) Deficiency  (1) Lysosomal Storage Disorders  (25) MabVax Therapeutics  (1) Macitentan  (1) MAKENA  (28) Malaria  (1) Mannitol  (4) Mantle Cell Lymphoma  (3) Mapp Pharmaceutical  (3) Marathon Pharmaceuticals  (1) Maroteaux-Lamy Syndrome  (1) Marqibo  (1) MassChallenge  (1) Mayo Clinic  (1) Medgenics  (1) Medical Marketing and Media  (13) Medivo  (3) Medullary Thyroid Cancer  (10) Meetings & Events  (63) Mekinist  (3) Melanoma  (7) Memorial Sloan Kettering Cancer Center  (1) Meningococcal B Disease  (5) Menkes Disease  (1) Merck  (7) Mexico  (8) Middle East  (2) Milo Biotechnology  (3) Miltefosine  (1) Mipomersen  (20) Mitochondrial Disease  (4) Molybdenum Cofactor Deficiency Type A  (1) Morquio A syndrome  (1) MPS II  (1) MPS VI  (1) MPS-I  (4) Mucopolysaccharidosis  (13) Multiple Myeloma  (8) Multiple Sclerosis  (1) Myasthenia Gravis  (1) Mydicar  (1) Myelodysplastic Syndrome  (1) Myelofibrosis  (5) National Institute of Health  (2) National Institutes of Health  (1) National Organization For Rare Disorders (NORD)  (2) Natpara  (2) Nephropathic Cystinosis  (2) Neuroblastoma  (3) Neurocrine Biosciences  (1) Newborn Screening  (12) Nexavar  (2) NICE  (4) Niemann-Pick Disease  (3) NightstaRx  (1) Nintedanib  (1) Nivolumab  (1) Non-Infectious Uveitis (NIU)  (1) Non-Small Cell Lung Cancer  (10) Novartis  (18) Novo Nordisk  (1) NPS Pharmaceuticals  (30) Nuplazid  (1) Obinutuzumab  (3) Obizur  (1) Octapharma  (3) Ofatumumab  (2) Ofev  (1) Olipudase Alfa  (1) Oncology  (32) OncoPep  (1) Onyx Pharmaceuticals  (4) Opaxio  (1) Opsumit  (1) Orphan Drug  (403) Orphan Drug Designation  (60) Orphan Drug Development  (527) Orphan Drug Exclusivity  (1) Orphan Drug Insurance Coverage  (1) Orphan Drug Pricing  (14) Orphan Drugs  (403) Orphan Drugs Going Generic  (1) Orphanet  (2) Osteogenesis Imperfecta  (1) Ovarian Cancer  (8) Paladin Therapeutics  (1) Palbociclib  (2) Palifosfamide  (3) Pancreatic Cancer  (1) Parkinson’s Disease Psychosis  (1) Pasireotide  (2) Patient Advocacy  (61) Patient Registries  (8) PDUFA Date  (23) Peanut Allergy  (1) Pembrolizumab  (3) Pentoxifylline  (2) Peripheral T-Cell Lymphoma  (2) Personalized Medicine  (2) Pfizer  (32) Pharmacyclics  (4) PharmaMar  (6) Pharmaxis  (5) Pharming  (1) Pharming N.V.  (1) Phenylketonuria (PKU)  (1) Pimavanserin  (1) Pirfenidone  (2) PlasmaTech Biopharmaceuticals  (2) Plexcera Therapeutics  (1) Pomalidomide  (7) Pomalyst  (5) Pompe Disease  (2) Ponatinib  (6) Portola Pharmaceuticals  (1) Postherpetic Neuralgia  (1) Pradaxa  (1) Priority Review Voucher  (1) Procysbi  (5) Profectus BioSciences  (1) Progeria  (3) Promacta  (2) ProQR Therapeutics  (1) Prosensa  (16) Protalix BioTherapeutics  (20) Provectus Biopharmaceuticals  (1) PsiOxus Therapeutics  (1) PTC Therapeutics  (8) PubMed Orphan Drug Abstracts  (13) Pulmonary Arterial Hypertension  (1) Quinacrine  (1) Ramucirumab  (1) Rapamune  (1) Raptor Pharmaceutical  (1) Rare Disease  (455) Rare Diseases  (500) Rare Genomics Institute  (1) Ravicti  (5) Raxibacumab  (2) Regeneron Pharmaceuticals  (5) REGENX Biosciences  (1) Regorafenib  (4) Retinitis Pigmentosa  (2) RetroSense Therapeutics  (2) Rett Syndrome  (2) Revestive  (10) Revlimid  (4) rEVO Biologics  (1) Revolade  (1) Rimeporide  (1) Rindopepimut  (1) Rintatolimod  (5) Rintega  (1) Roche  (4) Rucaparib  (1) Ruconest  (2) Ruxolitinib  (1) SAGE Therapeutics  (1) Salix Pharmaceuticals  (1) Sam Berns  (1) Sandhoff Disease  (2) Sanfilippo Syndrome  (7) Sangamo BioSciences  (1) Sanofi  (13) Sarepta Therapeutics  (49) Scioderm  (3) Seattle Genetics  (3) Sebelipase Alfa  (1) Serelaxin  (1) Severe Aplastic Anemia  (2) Severe Combined Immunodeficiency (SCID)  (3) SGX203  (1) Shire  (3) Shire plc  (22) Short Bowel Syndrome  (24) Sickle Cell Disease  (1) Signifor  (3) Sinopharm  (1) Sirolimus  (1) Sjögren-Larsson Syndrome  (1) SmartPhone Apps  (10) SOBI  (6) Social Media  (4) Sofosbuvir  (1) Soft Tissue Sarcoma  (3) Solid Ventures  (2) Soligenix  (1) Soliris  (19) Sorafenib  (2) Sovaldi  (1) Spark Therapeutics  (4) Spectrum Pharmaceuticals  (1) Spinal Muscular Atropy  (2) Sporadic Inclusion Body Myositis  (1) Start-Up  (12) Status Epilepticus  (1) Stem Cell Therapy  (2) Stivarga  (3) Summit plc  (3) Swedish Orphan Biovitrum  (1) Synageva BioPharma  (1) Syndax Pharmaceuticals  (2) Systemic anaplastic large cell lymphoma (sALCL)  (1) Tabalumab  (1) Taconic  (1) Tafenoquine  (1) Tafinlar  (4) TaiMed Biologics  (1) Takeda Pharmaceutical  (1) Takeda Pharmaceuticals  (7) Talon Therapeutics  (1) Tardive Dyskinesia  (1) Tay-Sachs  (2) Teduglutide  (29) Thanksgiving  (1) The Journal of Rare Disorders  (2) ThermoDox  (3) Thyroid Cancer  (2) Trametinib  (4) Trans Sodium Crocetinate  (1) Translarna  (2) Tretten  (1) Triptorelin Pamoate  (1) Trumenba  (2) Tufts Center for the Study of Drug Development  (2) UK  (3) Ultragenyx Pharmaceutical  (4) Uncategorized  (25) UniQure  (3) United Therapeutics  (1) Unituxin  (1) University of Florida  (1) University of South Florida  (1) Unniversity of Connecticut  (1) Uplyso  (2) US Biotest  (1) US Orphan Drug Development  (1) Usher Syndrome  (1) UX001 (Sialic Acid)  (2) Vaccine  (9) Vatiquinone  (1) Venetoclax  (1) Versartis  (1) Vertex Pharmaceuticals  (80) Viaskin Peanut  (1) Vimizim  (2) Vincerinone  (1) ViroPharma  (6) Vpriv  (11) VX-661  (1) Waldenstrom’s Macroglobulinemia  (1) Wilate  (3) World Orphan Drug Congress  (1) Worldwide Orphan Drug Policies  (5) X-Linked Myotubular Myopathy  (1) Xalkori  (3) Xenon Pharmaceuticals  (1) XOMA Corporation  (1) Ziopharm Oncology  (3) ZMapp  (4) Zydelig  (1) Zykadia  (1)

• CBI’s Expanded Access Programs

  

  The Orphan Druganaut Blog is a Media Partner.

• 2015 EVENT CALENDAR

  1) Orphan Drugs & Rare Diseases Global Congress 2015 Europe, London, UK, June 29 – July 1, 2015
  
  2) 2nd Rare Disease Collaboration Summit, Philadelphia, PA, July 15 - 16, 2015
  
  3) CBI's Expanded Access Programs, Bethesda, Maryland, July 22 - 23, 2015
  
  4) Orphan Drugs Summit 2015: Building a Collaborative Community, Copenhagen, Denmark, September 17 - 18, 2015
  
  5) Rare Disease Economics and Orphan Drug Commercialization, Boston, Massachusetts, September 28 - 29, 2015
  
  6) International Conference on Rare Diseases & Orphan Drugs (ICORD 2015), Mexico City, Mexico, October 15 - 16, 2015
  
  7) SMi’s Annual Orphan Drugs and Rare Diseases Conference, London, UK, October 19 - 20, 2015
  
  8) World Orphan Drug Congress Europe 2015, Geneva, Switzerland, November 12 - 13, 2015
  
  9) BioPharma Mexico, Mexico, November 18 - 19, 2015
  

• Cystic Fibrosis Duchenne Muscular Dystrophy European Medicines Agency (EMA) FDA Breakthrough Therapy Designation Ivacaftor Kalydeco Meetings & Events Orphan Drug Orphan Drug Designation Orphan Drug Development Orphan Drugs Patient Advocacy Rare Disease Rare Diseases Sarepta Therapeutics Vertex Pharmaceuticals

• COPYRIGHT

  Copyright © 2012-2015, Orphan Druganaut Blog. All rights reserved. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Orphan Druganaut Blog with appropriate and specific direction to the original content.